[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-fda-peptides-503a-vote-zh":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":9,"cat":10,"icon":11,"accent":12,"date":13,"dateLabel":14,"read":15,"author":16,"image":17,"body":18,"_type":523,"_id":524,"_source":525,"_file":526,"_stem":527,"_extension":528},"\u002Fblog\u002Fzh\u002Ffda-peptides-503a-vote","zh",false,"","FDA专家委员会投票支持BPC-157和TB-500：这改变了什么，又没改变什么","以下内容属于一般性科普，不构成医疗建议，也不是在建议你去获取或使用任何物质。它只是在解释一个监管流程。下文提到的肽都不是经FDA批准的药物，咨询委员会的一次投票不会让其中任何一种变得可以合法购买，本文也不含任何剂量或购买建议。","监管","tabler:building-bank","#3E7BB6","2026-07-24","2026年7月","9 min","myPeptides Team","\u002Fassets\u002Ffda_peptides_hero.png",{"type":19,"children":20,"toc":512},"root",[21,28,50,56,61,251,256,265,271,283,288,293,298,303,308,313,318,324,329,357,368,373,378,383,419,424,429,434],{"type":22,"tag":23,"props":24,"children":25},"element","p",{},[26],{"type":27,"value":9},"text",{"type":22,"tag":23,"props":29,"children":30},{},[31,33,39,41,48],{"type":27,"value":32},"一句话概括：2026年7月23日，FDA的药房配制咨询委员会（PCAC）投票，建议把四种肽——BPC-157、KPV、TB-500和MOTS-c——纳入那份清单，使配制药房可以合法制备它们。几场投票都很接近，而且结果",{"type":22,"tag":34,"props":35,"children":36},"strong",{},[37],{"type":27,"value":38},"与FDA自己的科学家意见相反",{"type":27,"value":40},"——后者曾建议对受审的全部七种肽都说\"不\"。这是最大的看点，也确实值得关注。但热闹之下被跳过的那部分才是关键：委员会投票是一项建议，而非决定。它不批准这些肽，不会把它们摆上药房货架，投票当天也没有改动一个字的法律。最终仍要由FDA拍板，而那要等到以后。这场会议为何召开，我们在投票前已在",{"type":22,"tag":42,"props":43,"children":45},"a",{"href":44},"\u002Fblog\u002Ffda-peptide-review-2026",[46],{"type":27,"value":47},"对2026年7月FDA听证会的解读",{"type":27,"value":49},"中写过。",{"type":22,"tag":51,"props":52,"children":54},"h2",{"id":53},"到底决定了什么",[55],{"type":27,"value":53},{"type":22,"tag":23,"props":57,"children":58},{},[59],{"type":27,"value":60},"PCAC在FDA位于银泉市的总部开了两天会。第一天（7月23日）审议BPC-157、KPV、TB-500和MOTS-c；第二天（7月24日）审议艾米地肽（DSIP）、Semax和Epitalon。每种肽单独投票，只回答一个问题：是否有足够依据把它列入503A条款下的\"原料药清单\"——一种物质必须先进入这份清单，药师才能合法用它进行配制。",{"type":22,"tag":62,"props":63,"children":64},"table",{},[65,94],{"type":22,"tag":66,"props":67,"children":68},"thead",{},[69],{"type":22,"tag":70,"props":71,"children":72},"tr",{},[73,79,84,89],{"type":22,"tag":74,"props":75,"children":76},"th",{},[77],{"type":27,"value":78},"肽",{"type":22,"tag":74,"props":80,"children":81},{},[82],{"type":27,"value":83},"委员会审议的背景",{"type":22,"tag":74,"props":85,"children":86},{},[87],{"type":27,"value":88},"投票（赞成–反对–弃权）",{"type":22,"tag":74,"props":90,"children":91},{},[92],{"type":27,"value":93},"建议",{"type":22,"tag":95,"props":96,"children":97},"tbody",{},[98,122,143,164,186,209,230],{"type":22,"tag":70,"props":99,"children":100},{},[101,107,112,117],{"type":22,"tag":102,"props":103,"children":104},"td",{},[105],{"type":27,"value":106},"BPC-157",{"type":22,"tag":102,"props":108,"children":109},{},[110],{"type":27,"value":111},"肠道与组织修复（溃疡性结肠炎）",{"type":22,"tag":102,"props":113,"children":114},{},[115],{"type":27,"value":116},"8–6–1",{"type":22,"tag":102,"props":118,"children":119},{},[120],{"type":27,"value":121},"列入清单",{"type":22,"tag":70,"props":123,"children":124},{},[125,130,135,139],{"type":22,"tag":102,"props":126,"children":127},{},[128],{"type":27,"value":129},"KPV",{"type":22,"tag":102,"props":131,"children":132},{},[133],{"type":27,"value":134},"创面愈合、炎症",{"type":22,"tag":102,"props":136,"children":137},{},[138],{"type":27,"value":116},{"type":22,"tag":102,"props":140,"children":141},{},[142],{"type":27,"value":121},{"type":22,"tag":70,"props":144,"children":145},{},[146,151,156,160],{"type":22,"tag":102,"props":147,"children":148},{},[149],{"type":27,"value":150},"TB-500",{"type":22,"tag":102,"props":152,"children":153},{},[154],{"type":27,"value":155},"创面与组织修复",{"type":22,"tag":102,"props":157,"children":158},{},[159],{"type":27,"value":116},{"type":22,"tag":102,"props":161,"children":162},{},[163],{"type":27,"value":121},{"type":22,"tag":70,"props":165,"children":166},{},[167,172,177,182],{"type":22,"tag":102,"props":168,"children":169},{},[170],{"type":27,"value":171},"MOTS-c",{"type":22,"tag":102,"props":173,"children":174},{},[175],{"type":27,"value":176},"代谢、体重",{"type":22,"tag":102,"props":178,"children":179},{},[180],{"type":27,"value":181},"7–5–2",{"type":22,"tag":102,"props":183,"children":184},{},[185],{"type":27,"value":121},{"type":22,"tag":70,"props":187,"children":188},{},[189,194,199,204],{"type":22,"tag":102,"props":190,"children":191},{},[192],{"type":27,"value":193},"艾米地肽（DSIP）",{"type":22,"tag":102,"props":195,"children":196},{},[197],{"type":27,"value":198},"睡眠",{"type":22,"tag":102,"props":200,"children":201},{},[202],{"type":27,"value":203},"第二天——截稿时尚无最终结果",{"type":22,"tag":102,"props":205,"children":206},{},[207],{"type":27,"value":208},"待定",{"type":22,"tag":70,"props":210,"children":211},{},[212,217,222,226],{"type":22,"tag":102,"props":213,"children":214},{},[215],{"type":27,"value":216},"Semax",{"type":22,"tag":102,"props":218,"children":219},{},[220],{"type":27,"value":221},"认知",{"type":22,"tag":102,"props":223,"children":224},{},[225],{"type":27,"value":203},{"type":22,"tag":102,"props":227,"children":228},{},[229],{"type":27,"value":208},{"type":22,"tag":70,"props":231,"children":232},{},[233,238,243,247],{"type":22,"tag":102,"props":234,"children":235},{},[236],{"type":27,"value":237},"Epitalon",{"type":22,"tag":102,"props":239,"children":240},{},[241],{"type":27,"value":242},"长寿",{"type":22,"tag":102,"props":244,"children":245},{},[246],{"type":27,"value":203},{"type":22,"tag":102,"props":248,"children":249},{},[250],{"type":27,"value":208},{"type":22,"tag":23,"props":252,"children":253},{},[254],{"type":27,"value":255},"第一天的四种肽都过了，但请看票差：8比6、外加一票弃权，距离平局只差一票。这不是众口一词的信任，而是一群意见分歧的委员勉强倒向了\"放开\"。第二天的三种肽在本文付印时仍在讨论；结果一旦公开，我们会补进表格，而不是在这里瞎猜。",{"type":22,"tag":23,"props":257,"children":258},{},[259],{"type":22,"tag":260,"props":261,"children":264},"img",{"alt":262,"src":263},"七个多肽西林瓶旁边放着一张核对清单，其中四个已打勾","\u002Fassets\u002Ffda_peptides_seven.png",[],{"type":22,"tag":51,"props":266,"children":268},{"id":267},"为什么fda自己的科学家说不",[269],{"type":27,"value":270},"为什么FDA自己的科学家说\"不\"",{"type":22,"tag":23,"props":272,"children":273},{},[274,276,281],{"type":27,"value":275},"正是这一点，让故事比\"委员会放行肽类\"更有意思。FDA的审评人员建议驳回",{"type":22,"tag":34,"props":277,"children":278},{},[279],{"type":27,"value":280},"全部七种",{"type":27,"value":282},"，而他们给出的理由不是小题大做，是证据。",{"type":22,"tag":23,"props":284,"children":285},{},[286],{"type":27,"value":287},"说白了，他们的核心意思是：这些物质表征不清，关于它们到底有没有效的人体数据少得可怜，甚至根本没有。就BPC-157而言，审评人员说他们基本上只找到一篇小型试验的摘要——大约46人，而且是以灌肠方式给药，并非人们实际使用的注射。就KPV而言，他们没有找到任何人体试验。安全性数据有限，免疫原性风险——即身体对注射进来的肽产生免疫反应的可能——在很大程度上未经评估；而对溃疡性结肠炎这类疾病，已经有越过这道门槛的获批药物。再叠加配制本身的隐忧：配制产品的差错率高于工业化生产的产品，而2025年一项针对药房配制GLP-1药物的分析发现，其不良反应多于已获批的对应产品。这些都不是在说这些肽有害——而是在说，放行所需的证据眼下根本还不够。",{"type":22,"tag":23,"props":289,"children":290},{},[291],{"type":27,"value":292},"委员会成员之一、UT MD安德森癌症中心的麻醉医生Elizabeth Rebello直言不讳地道出反对意见：\"我担心我们是在回应市场制造出来的需求，而不是在做一个建立在扎实科学之上的决定。\"这正是反对票的关键：不是说这些肽已被证明有害，而是说流行本身并不构成证据。",{"type":22,"tag":51,"props":294,"children":296},{"id":295},"利益冲突这道坎",[297],{"type":27,"value":295},{"type":22,"tag":23,"props":299,"children":300},{},[301],{"type":27,"value":302},"不了解谁坐在会议室里，就无法公允地读这次投票。委员会在会前不久被大改：十二名成员中有八名是2026年6月底任命的，而据STAT等媒体报道，这些新任命者中除一人外，都与销售或注射肽类的企业存在财务往来。被点名的例子包括：一名医生担任某男性健康连锁诊所的医务主管，而该诊所出售肽类注射；一名医生对肽类咨询收费并推广BPC-157；还有一名药师在自家的配制药房工作。",{"type":22,"tag":23,"props":304,"children":305},{},[306],{"type":27,"value":307},"这可不是无关紧要的细节。当投票放开某种产品的人，在不少情况下正是从这种放开中获利的人，这次投票就该受到和任何游说一样的质疑——正因如此，反对意见和FDA科学家的立场作为制衡才如此重要。值得肯定的是，该机构增补了几名具有学术与临床研究背景的临时表决成员，以冲淡这种担忧；但批评是实打实的，读上面那些8比6的票差时值得放在心上。就连投赞成票的成员，也是站在患者安全的角度：新任命者之一Haleem Mohammed医生辩称：\"作为医生，我必须尽力让患者尽可能安全。这是我的职责，对吧？首先，不造成伤害。\"这两种想法可以同时成立：动机也许是真诚的，冲突也依然可能扭曲结果。",{"type":22,"tag":51,"props":309,"children":311},{"id":310},"最先动的是钱",[312],{"type":27,"value":310},{"type":22,"tag":23,"props":314,"children":315},{},[316],{"type":27,"value":317},"一个值得留意的信号：BPC-157投票之后，Hims & Hers——一家有望从更广泛的配制肽类渠道中获益的远程医疗公司——股价上涨超过10%。法律没有改变。没有任何一种肽获批。没有任何一家药房拿到新权利。委员会只是向FDA提了个建议，市场却在一天之内让一只股票涨了两位数。真正发生的（一项不具约束力的建议）与被外界解读成的（放行）之间的这道落差，正是我们要冷静下笔的全部理由。市场能抢在事实前面，一封冲着你来的营销邮件也一样。",{"type":22,"tag":51,"props":319,"children":321},{"id":320},"对患者和诊所改变了什么又没改变什么",[322],{"type":27,"value":323},"对患者和诊所改变了什么，又没改变什么",{"type":22,"tag":23,"props":325,"children":326},{},[327],{"type":27,"value":328},"我们把话说准，因为这一段最容易被扭曲。",{"type":22,"tag":23,"props":330,"children":331},{},[332,334,339,341,347,349,355],{"type":27,"value":333},"7月23日",{"type":22,"tag":34,"props":335,"children":336},{},[337],{"type":27,"value":338},"没有",{"type":27,"value":340},"改变的：这些肽中任何一种的法律地位。BPC-157、TB-500、KPV和MOTS-c今天的合法程度——无论合法与否——都和投票前一天一模一样。没有一种成了获批药物。没有一种因为这次投票就成了药房当下可以配制的东西。此刻有人卖给你、贴着\"BPC-157\"或\"TB-500\"标签的任何东西，不论是包装成保健品还是标着\"仅供研究\"，仍然是未获批的灰色市场货，其真伪与纯度都无从核实。委员会的一句意见，既不能让一支西林瓶变干净，也不能替你核验瓶里到底装了什么。完整的法律图景，可读我们的支柱文章",{"type":22,"tag":42,"props":342,"children":344},{"href":343},"\u002Fare-peptides-legal",[345],{"type":27,"value":346},"肽类合法吗",{"type":27,"value":348},"；而",{"type":22,"tag":42,"props":350,"children":352},{"href":351},"\u002Ffda-approved-peptides",[353],{"type":27,"value":354},"经FDA批准的肽",{"type":27,"value":356},"会告诉你哪些肽真正通过了批准——那是一份很不一样、也短得多的清单。",{"type":22,"tag":23,"props":358,"children":359},{},[360,366],{"type":22,"tag":361,"props":362,"children":363},"em",{},[364],{"type":27,"value":365},"以后",{"type":27,"value":367},"可能改变的：如果FDA采纳建议，这些肽就会获得一条合法的配制途径。久而久之，这通常意味着凭处方、更稳定、药房级别的产品，也意味着更少理由去碰灰色市场。这是乐观的一面，而且真实存在。但这只是一种尚未发生的可能，前提是FDA点头——而这个决定还没做出。",{"type":22,"tag":51,"props":369,"children":371},{"id":370},"接下来会怎样",[372],{"type":27,"value":370},{"type":22,"tag":23,"props":374,"children":375},{},[376],{"type":27,"value":377},"委员会提建议，FDA作决定。眼下该机构在权衡这项建议，决定是否启动正式的立法程序，把其中某些肽列入503A清单——这个过程实际上会持续许多个月，可能一直拖到2027年。它可以采纳建议、否决建议，也可以逐个肽地落在两者之间。第二天关于艾米地肽、Semax和Epitalon的投票会补齐其余画面；结果一经公开，我们就会用确认过的票数更新本文。",{"type":22,"tag":23,"props":379,"children":380},{},[381],{"type":27,"value":382},"诚实的结论既不是\"肽类回来了\"，也不是\"肽类被禁了\"。而是：7月23日，少数几种具体的肽，其处境确实开始松动——朝着最终合法配制的方向——但截至今天，它们仍停在原地：未获批、未受监管、灰色市场。盯住这一动向是明智的；把它当成已经尘埃落定，则不然。",{"type":22,"tag":23,"props":384,"children":385},{},[386,388,394,396,402,404,409,411,417],{"type":27,"value":387},"如果你本就在记录肽类，把自己有什么、浓度多少、什么时候用的记清楚——这正是",{"type":22,"tag":42,"props":389,"children":391},{"href":390},"\u002Fpeptides-list",[392],{"type":27,"value":393},"我们的肽类追踪器",{"type":27,"value":395},"的用途——远比任何论坛对一次委员会投票的解读更有价值。想从头理解这一类物质，先看",{"type":22,"tag":42,"props":397,"children":399},{"href":398},"\u002Fwhat-are-peptides",[400],{"type":27,"value":401},"什么是肽",{"type":27,"value":403},"；想了解这次会议之前的来龙去脉，看",{"type":22,"tag":42,"props":405,"children":406},{"href":44},[407],{"type":27,"value":408},"FDA听证会解读",{"type":27,"value":410},"；至于如何冷静地读一个大标题，我们那篇关于",{"type":22,"tag":42,"props":412,"children":414},{"href":413},"\u002Fblog\u002Fretatrutide-triumph-1-results",[415],{"type":27,"value":416},"瑞他鲁肽TRIUMPH-1",{"type":27,"value":418},"的姊妹文，讲的正是同一种冷静的读法，只不过换到了另一种药上。",{"type":22,"tag":51,"props":420,"children":422},{"id":421},"结语",[423],{"type":27,"value":421},{"type":22,"tag":23,"props":425,"children":426},{},[427],{"type":27,"value":428},"FDA一个咨询委员会以微弱多数建议将BPC-157、KPV、TB-500和MOTS-c纳入配制范围，越过了自己的科学家——与此同时，谁在投票是个真问题，而支持任何一种肽有效的人体证据都很单薄。建议不是批准，FDA尚未定夺，投票当天购买这些肽既没有变得更安全，也没有变得更合法。把这个结果读作规则\"可能改变\"的信号，而不是读作它\"已经改变\"的许可。",{"type":22,"tag":51,"props":430,"children":432},{"id":431},"参考来源",[433],{"type":27,"value":431},{"type":22,"tag":435,"props":436,"children":437},"ul",{},[438,452,464,476,488,500],{"type":22,"tag":439,"props":440,"children":441},"li",{},[442,444],{"type":27,"value":443},"FDA，",{"type":22,"tag":42,"props":445,"children":449},{"href":446,"rel":447},"https:\u002F\u002Fwww.fda.gov\u002Fadvisory-committees\u002Fadvisory-committee-calendar\u002Fjuly-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026",[448],"nofollow",[450],{"type":27,"value":451},"药房配制咨询委员会会议，2026年7月23日至24日",{"type":22,"tag":439,"props":453,"children":454},{},[455,457],{"type":27,"value":456},"TIME，",{"type":22,"tag":42,"props":458,"children":461},{"href":459,"rel":460},"https:\u002F\u002Ftime.com\u002Farticle\u002F2026\u002F07\u002F23\u002Ffda-committee-peptides\u002F",[448],[462],{"type":27,"value":463},"An FDA committee just voted in favor of peptides — despite the agency's opposition",{"type":22,"tag":439,"props":465,"children":466},{},[467,469],{"type":27,"value":468},"STAT，",{"type":22,"tag":42,"props":470,"children":473},{"href":471,"rel":472},"https:\u002F\u002Fwww.statnews.com\u002F2026\u002F07\u002F23\u002Ffda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv\u002F",[448],[474],{"type":27,"value":475},"FDA panel backs compounded BPC-157, KPV peptides in win for RFK Jr.",{"type":22,"tag":439,"props":477,"children":478},{},[479,481],{"type":27,"value":480},"RAPS，",{"type":22,"tag":42,"props":482,"children":485},{"href":483,"rel":484},"https:\u002F\u002Fwww.raps.org\u002Fresource\u002Ffda-advisory-committee-backs-two-controversial-peptides.html",[448],[486],{"type":27,"value":487},"FDA advisory committee backs two controversial peptides",{"type":22,"tag":439,"props":489,"children":490},{},[491,493],{"type":27,"value":492},"BioPharma Dive，",{"type":22,"tag":42,"props":494,"children":497},{"href":495,"rel":496},"https:\u002F\u002Fwww.biopharmadive.com\u002Fnews\u002Ffda-peptides-advisory-committee-vote-bpc-kpv-tb-mots\u002F826062\u002F",[448],[498],{"type":27,"value":499},"FDA panel endorses broader use of certain peptides",{"type":22,"tag":439,"props":501,"children":502},{},[503,505],{"type":27,"value":504},"The Hill，",{"type":22,"tag":42,"props":506,"children":509},{"href":507,"rel":508},"https:\u002F\u002Fthehill.com\u002Fhomenews\u002F5987510-fda-committee-votes-peptides\u002F",[448],[510],{"type":27,"value":511},"FDA committee votes to add peptides to permitted compounding list despite opposition from agency scientists",{"title":7,"searchDepth":513,"depth":513,"links":514},2,[515,516,517,518,519,520,521,522],{"id":53,"depth":513,"text":53},{"id":267,"depth":513,"text":270},{"id":295,"depth":513,"text":295},{"id":310,"depth":513,"text":310},{"id":320,"depth":513,"text":323},{"id":370,"depth":513,"text":370},{"id":421,"depth":513,"text":421},{"id":431,"depth":513,"text":431},"markdown","content:blog:zh:fda-peptides-503a-vote.md","content","blog\u002Fzh\u002Ffda-peptides-503a-vote.md","blog\u002Fzh\u002Ffda-peptides-503a-vote","md"]